Comparative Pharmacology
Head-to-head clinical analysis: HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE versus QBREXZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE versus QBREXZA.
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE vs QBREXZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; homatropine methylbromide is an anticholinergic that reduces gastrointestinal motility and secretions.
Selective D1 and D5 dopamine receptor antagonist; reduces dopamine-mediated vasodilation in choroidal blood vessels, decreasing choroidal thickness and neovascularization.
1 tablet (containing homatropine methylbromide 5 mg and hydrocodone bitartrate 5 mg) orally every 4 to 6 hours as needed for cough. Maximum 6 tablets per 24 hours.
1 capsule (40 mg) orally twice daily with or without food.
None Documented
None Documented
Hydrocodone: Terminal elimination half-life 3.8-6.4 hours (mean ~4.5 h) in adults; prolonged in hepatic/renal impairment (up to 12-15 h). Homatropine methylbromide: Terminal half-life ~4-6 hours via quaternary structure limiting CNS penetration.
Terminal elimination half-life is approximately 150 hours (range 120-200 hours), supporting once-daily dosing without significant accumulation.
Hydrocodone: Renal excretion of metabolites (hydromorphone, norhydrocodone) as glucuronide conjugates (~60%) and unchanged drug (<10%). Biliary/fecal elimination accounts for ~20-30%. Homatropine methylbromide: Predominantly fecal elimination via biliary excretion as unchanged quaternary ammonium compound (~70-80%); renal excretion of unchanged drug (~10-20%).
Renal: approximately 30% as unchanged drug; fecal: approximately 60% as metabolites and parent compound; biliary excretion contributes to fecal elimination.
Category D/X
Category C
Anticholinergic
Anticholinergic